Skip to content

Advertisement

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 4 of 9

  1. Content type: Research article

    The radiopharmaceutical 131I-meta-iodobenzylguanidine (131I-MIBG) is an effective treatment for neuroblastoma. However, maximal therapeutic benefit from 131I-MIBG is likely to be obtained by its combination with ...

    Authors: Donna L. Nile, Colin Rae, Iain J. Hyndman, Mark N. Gaze and Robert J. Mairs

    Citation: BMC Cancer 2016 16:621

    Published on:

  2. Content type: Research article

    Cyclophosphamide (CPA) can activate immunogenic tumor cell death, which induces immune-based tumor ablation and long-term anti-tumor immunity in a syngeneic C57BL/6 (B6) mouse GL261 glioma model when CPA is gi...

    Authors: Junjie Wu, Marie Jordan and David J. Waxman

    Citation: BMC Cancer 2016 16:623

    Published on:

  3. Content type: Research article

    Due to lack of a targeted therapy for the triple-negative breast cancer (TNBC) patients, it is important to explore this aggressive breast cancer type in more detail and to establish novel therapeutic approach...

    Authors: Michaela C. Huber, Rebecca Mall, Herbert Braselmann, Annette Feuchtinger, Sara Molatore, Katrin Lindner, Axel Walch, Eva Gross, Manfred Schmitt, Natalie Falkenberg and Michaela Aubele

    Citation: BMC Cancer 2016 16:615

    Published on:

  4. Content type: Research article

    Chemoresistance is one of the most leading causes for tumor progression and recurrence of bladder cancer. Reactive oxygen species (ROS) plays a key role in the chemosensitivity of cancer cells. In the present ...

    Authors: Xinxing Li, Haolu Wang, Juan Wang, Yuying Chen, Xiaobin Yin, Guiying Shi, Hui Li, Zhiqian Hu and Xiaowen Liang

    Citation: BMC Cancer 2016 16:578

    Published on:

  5. Content type: Research article

    Cell-penetrating peptides (CPPs) are a research hotspot due to their noninvasive delivery ability. Among the identified CPPs, the TAT and R8 peptides have been preferentially applied to transduction into diffe...

    Authors: Lifeng Wang, Haijin Chen, Jinlong Yu, Xiaohua Lin, Jia Qi, Chunhui Cui, Lang Xie and Shuxin Huang

    Citation: BMC Cancer 2016 16:571

    Published on:

  6. Content type: Research article

    Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Therefore, nove...

    Authors: Huda A. Al-Howail, Hana A. Hakami, Basem Al-Otaibi, Amer Al-Mazrou, Maha H. Daghestani, Ibrahim Al-Jammaz, Huda H. Al-Khalaf and Abdelilah Aboussekhra

    Citation: BMC Cancer 2016 16:540

    Published on:

  7. Content type: Research article

    Directly targeting therapeutic suicide gene to a solid tumor is a hopeful approach for cancer gene therapy. Treatment of a solid tumor by an effective vector for a suicide gene remains a challenge. Given the l...

    Authors: Changdong Wang, Yongping Ma, Qiongwen Hu, Tingting Xie, Jiayan Wu, Fan Zeng and Fangzhou Song

    Citation: BMC Cancer 2016 16:545

    Published on:

  8. Content type: Research article

    The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radioth...

    Authors: Koji Harada, Tarannum Ferdous, Dan Cui, Yasuhiro Kuramitsu, Takuya Matsumoto, Eiji Ikeda, Hideyuki Okano and Yoshiya Ueyama

    Citation: BMC Cancer 2016 16:548

    Published on:

  9. Content type: Research article

    Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation of the AKT pathway promotes platinum resistance while inhibition of AKT sensitizes chemoresistant cells. ...

    Authors: Margaret E. Whicker, Z. Ping Lin, Ruth Hanna, Alan C. Sartorelli and Elena S. Ratner

    Citation: BMC Cancer 2016 16:550

    Published on:

  10. Content type: Research article

    Preclinical research indicate that vascular disrupting agent (VDA) treatment induces extensive tumor death but also a systemic mobilization of bone marrow derived cells including endothelial progenitor cells (...

    Authors: Linh Nguyen, Theodora Fifis and Christopher Christophi

    Citation: BMC Cancer 2016 16:533

    Published on:

  11. Content type: Research article

    The use of targeted agents to impel dual inhibition of anti-apoptotic mechanisms and mTOR-mediated pro-survival signaling in colorectal carcinoma (CRC) cell lines with KRAS or BRAF mutation has been shown to indu...

    Authors: Karianne Risberg, Kathrine Røe Redalen, Linda Sønstevold, Tonje Bjørnetrø, Janne Sølvernes and Anne Hansen Ree

    Citation: BMC Cancer 2016 16:531

    Published on:

  12. Content type: Research article

    We recently demonstrated the cytotoxicity of liquid crystal precursors (hereafter referred to as “mesogenic compounds”) in the human non-small cell lung cancer (NSCLC) cell line A549 which carry wild-type p53....

    Authors: Saori Fukushi, Hironori Yoshino, Atsushi Yoshizawa and Ikuo Kashiwakura

    Citation: BMC Cancer 2016 16:521

    Published on:

  13. Content type: Research article

    Success of cancer prodrugs relying on a foreign gene requires specific delivery of the gene to the cancer, and improvements such as higher level gene transfer and expression. Attaining these objectives will be...

    Authors: Jing-Hung Wang, Aaron N. Endsley, Carol E. Green and A. C. Matin

    Citation: BMC Cancer 2016 16:524

    Published on:

  14. Content type: Research article

    Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth o...

    Authors: Meihua Liang, Fei Zhan, Juan Zhao, Qi Li, Jiazi Wuyang, Guannan Mu, Dianjun Li, Yanqiao Zhang and Xiaoyi Huang

    Citation: BMC Cancer 2016 16:504

    Published on:

  15. Content type: Research article

    Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired ...

    Authors: Ren Zhao, Shun Zhou, Bing Xia, Cui-ying Zhang, Ping Hai, Hong Zhe and Yan-yang Wang

    Citation: BMC Cancer 2016 16:491

    Published on:

  16. Content type: Research article

    Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to s...

    Authors: Hideo Morioka, Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Mitsuru Takahashi, Tsukasa Yonemoto, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Michiro Susa, Robert Nakayama, Kazumasa Nishimoto, Kazutaka Kikuta, Keisuke Horiuchi…

    Citation: BMC Cancer 2016 16:479

    Published on:

  17. Content type: Research article

    Endocannabinoids have recently drawn attention as promising anti-cancer agents. We previously observed that anandamide (AEA), one of the representative endocannabinoids, effectively inhibited the proliferation...

    Authors: Seok-Woo Park, J. Hun Hah, Sang-Mi Oh, Woo-Jin Jeong and Myung-Whun Sung

    Citation: BMC Cancer 2016 16:458

    Published on:

  18. Content type: Research article

    Approximately 80 % of mesothelioma specimens have the wild-type p53 gene, whereas they contain homozygous deletions in the INK4A/ARF locus that encodes p14 ARF ...

    Authors: Yuanyuan Jiang, Boya Zhong, Kiyoko Kawamura, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima and Masatoshi Tagawa

    Citation: BMC Cancer 2016 16:455

    Published on:

  19. Content type: Research article

    The natural compound triptolide has been shown to decrease cell proliferation and induce apoptosis and cellular senescence. We previously demonstrated that triptolide decreases tumor formation and metastasis o...

    Authors: Theresa A. Reno, Sun-Wing Tong, Jun Wu, John M. Fidler, Rebecca Nelson, Jae Y. Kim and Dan J. Raz

    Citation: BMC Cancer 2016 16:439

    Published on:

  20. Content type: Research article

    Previous work has demonstrated immunomodulatory, anti-tumor, anti-metastatic and anti-angiogenic effects of the small molecule quinoline-3-carboxamide tasquinimod in pre-clinical cancer models. To better under...

    Authors: Adnan Deronic, Sahar Tahvili, Tomas Leanderson and Fredrik Ivars

    Citation: BMC Cancer 2016 16:440

    Published on:

    The Erratum to this article has been published in BMC Cancer 2016 16:610

  21. Content type: Research article

    Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.

    Authors: N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G. M. Haag, M. Rieger, O. G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran

    Citation: BMC Cancer 2016 16:420

    Published on:

  22. Content type: Research article

    The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of ...

    Authors: Patrick Vianna Garcia, Fábio Rodrigues Ferreira Seiva, Amanda Pocol Carniato, Wilson de Mello Júnior, Nelson Duran, Alda Maria Macedo, Alexandre Gabarra de Oliveira, Rok Romih, Iseu da Silva Nunes, Odilon da Silva Nunes and Wagner José Fávaro

    Citation: BMC Cancer 2016 16:422

    Published on:

  23. Content type: Research article

    We previously demonstrated that hsa-miR-520d-5p can convert cancer cells into induced pluripotent stem cells (iPSCs) or mesenchymal stem cells (MSCs) via a demethylation process and p53 upregulation in vivo. A...

    Authors: Yoshitaka Ishihara, Satoshi Tsuno, Satoshi Kuwamoto, Taro Yamashita, Yusuke Endo, Keigo Miura, Yugo Miura, Takemasa Sato, Junichi Hasegawa and Norimasa Miura

    Citation: BMC Cancer 2016 16:415

    Published on:

    The Correction to this article has been published in BMC Cancer 2017 17:666

  24. Content type: Research article

    Cancer-cachexia state frequently induces both fat and protein wasting, leading to death. In this way, the knowledge of the mechanism of drugs and their side effects can be a new feature to treat and to have su...

    Authors: André G. Oliveira and Maria Cristina C. Gomes-Marcondes

    Citation: BMC Cancer 2016 16:418

    Published on:

  25. Content type: Research article

    L-Arg is involved in many biological activities, including the activation of T cells. In breast cancer patients, L-Arg is depleted by nitric oxide synthase 2 (NOS2) and arginase 1 (ARG-1) produced by myeloid-d...

    Authors: Yu Cao, Yonghui Feng, Yanjun Zhang, Xiaotong Zhu and Feng Jin

    Citation: BMC Cancer 2016 16:343

    Published on:

  26. Content type: Research article

    Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions ...

    Authors: Keisuke Takeda, Noboru Hara, Tsutomu Nishiyama, Masayuki Tasaki, Fumio Ishizaki and Yoshihiko Tomita

    Citation: BMC Cancer 2016 16:332

    Published on:

  27. Content type: Research article

    The synthesis of specific, potent progesterone antagonists adds potential agents to the breast cancer prevention and treatment armamentarium. The identification of individuals who will benefit from these agent...

    Authors: Susan E. Clare, Akash Gupta, MiRan Choi, Manish Ranjan, Oukseub Lee, Jun Wang, David Z. Ivancic, J. Julie Kim and Seema A. Khan

    Citation: BMC Cancer 2016 16:326

    Published on:

  28. Content type: Research article

    Transarterial chemoembolization is one of the most widely accepted interventional treatment options for treatment of hepatocellular carcinoma. Still there is a lack of a standard protocol regarding the injecte...

    Authors: Thomas J. Vogl, Elsie Oppermann, Jun Qian, Ulli Imlau, Andreas Tran, Yousef Hamidavi, Huedayi Korkusuz, Wolf Otto Bechstein, Nour-Eldin Abdel-Rehim Nour-Eldin, Tatjana Gruber-Rouh, Renate Hammerstingl and Nagy Naguib Naeem Naguib

    Citation: BMC Cancer 2016 16:325

    Published on:

  29. Content type: Research article

    Acquired resistance towards apoptosis is a hallmark of cancer. Elimination of cells bearing activated oncogenes or stimulation of tumor suppressor mediators may provide a selection pressure to overcome resista...

    Authors: Christiana G. Savva, Sotirios Totokotsopoulos, Kyriakos C. Nicolaou, Christiana M. Neophytou and Andreas I. Constantinou

    Citation: BMC Cancer 2016 16:279

    Published on:

  30. Content type: Research article

    Despite recent progress, investigating the impact of targeted therapies on Head and Neck Squamous Cell Carcinoma (HNSCC) remains a challenge. We investigated whether short-term culture of tumour fragments woul...

    Authors: Jérôme Donnadieu, Emma Lachaier, Marine Peria, Zuzana Saidak, Stéphanie Dakpe, Jean-Fortune Ikoli, Bruno Chauffert, Cyril Page and Antoine Galmiche

    Citation: BMC Cancer 2016 16:273

    Published on:

  31. Content type: Research article

    Hepcidin, a key regulator of iron metabolism, is produced mainly by interleukin-6 (IL-6) during inflammation. A mechanism linking cancer-related anemia and IL-6 through hepcidin production is suggested. To cla...

    Authors: Mariko Noguchi-Sasaki, Yusuke Sasaki, Yasushi Shimonaka, Kazushige Mori and Kaori Fujimoto-Ouchi

    Citation: BMC Cancer 2016 16:270

    Published on:

  32. Content type: Research article

    Melphalan has been used in the treatment of various hematologic malignancies for almost 60 years. Today it is part of standard therapy for multiple myeloma and also as part of myeloablative regimens in associa...

    Authors: Maryam Delforoush, Sara Strese, Malin Wickström, Rolf Larsson, Gunilla Enblad and Joachim Gullbo

    Citation: BMC Cancer 2016 16:263

    Published on:

  33. Content type: Research article

    Luteinizing hormone-releasing hormone receptor (LHRHr) represents a promising therapeutic target for treating sex hormone-dependent tumors. We coupled cecropin B, an antimicrobial peptide, to LHRH’, a form of ...

    Authors: Xiaoyong Li, Bo Shen, Qi Chen, Xiaohui Zhang, Yiqing Ye, Fengmei Wang and Xinmei Zhang

    Citation: BMC Cancer 2016 16:251

    Published on:

  34. Content type: Research article

    The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those prote...

    Authors: Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min and Kwang-Ai Won

    Citation: BMC Cancer 2016 16:247

    Published on:

  35. Content type: Research article

    Eliminating cancer stem cells (CSCs) has been suggested for prevention of tumor recurrence and metastasis. Honokiol, an active compound of Magnolia officinalis, had been proposed to be a potential candidate drug ...

    Authors: Jhy-Shrian Huang, Chih-Jung Yao, Shuang-En Chuang, Chi-Tai Yeh, Liang-Ming Lee, Ruei-Ming Chen, Wan-Ju Chao, Jacqueline Whang-Peng and Gi-Ming Lai

    Citation: BMC Cancer 2016 16:245

    Published on:

  36. Content type: Research article

    Nanomedicine is a very promising field and nanomedical drugs have recently been used as therapeutic agents against cancer. In a previous study, we showed that Nanoceria (NCe), nanoparticles of cerium oxide, si...

    Authors: Miriana Hijaz, Soumen Das, Ismail Mert, Ankur Gupta, Zaid Al-Wahab, Calvin Tebbe, Sajad Dar, Jasdeep Chhina, Shailendra Giri, Adnan Munkarah, Sudipta Seal and Ramandeep Rattan

    Citation: BMC Cancer 2016 16:220

    Published on:

  37. Content type: Research article

    Alpha-tocopheryloxyacetic acid (α-TEA) is a semi-synthetic derivative of naturally occurring vitamin E (alpha-tocopherol) that can be delivered via an oral route. Preclinical in vitro and in vivo data demonstr...

    Authors: Bella S. Guerrouahen, Tobias Hahn, Zefora Alderman, Brendan Curti, Walter Urba and Emmanuel T. Akporiaye

    Citation: BMC Cancer 2016 16:199

    Published on:

  38. Content type: Research article

    Group IVA cytosolic phospholipase A2 (cPLA2α) plays an important role in tumorigenesis and angiogenesis. It is overexpressed in basal-like breast cancer (BLBC), which is aggressive and usually triple-negative,...

    Authors: Eugene Kim, Hanna Maja Tunset, Jana Cebulla, Riyas Vettukattil, Heidi Helgesen, Astrid Jullumstrø Feuerherm, Olav Engebråten, Gunhild Mari Mælandsmo, Berit Johansen and Siver Andreas Moestue

    Citation: BMC Cancer 2016 16:191

    Published on:

  39. Content type: Research article

    Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as cancer-a...

    Authors: Melanie Mediavilla-Varela, Kingsley Boateng, David Noyes and Scott J. Antonia

    Citation: BMC Cancer 2016 16:176

    Published on:

  40. Content type: Research article

    Novel therapies are needed for children with high-risk and relapsed neuroblastoma. We hypothesized that MAPK/ERK kinase (MEK) inhibition with the novel MEK1/2 inhibitor binimetinib would be effective in neurob...

    Authors: Sarah E. Woodfield, Linna Zhang, Kathleen A. Scorsone, Yin Liu and Peter E. Zage

    Citation: BMC Cancer 2016 16:172

    Published on:

  41. Content type: Research article

    Platinum-based drugs are used as cancer chemotherapeutics for the last 40 years. However, drug resistance and nephrotoxicity are the major limitations of the use of platinum-based compounds in cancer therapy. ...

    Authors: Einav Ratzon, Yousef Najajreh, Rami Salem, Hazem Khamaisie, Martin Ruthardt and Jamal Mahajna

    Citation: BMC Cancer 2016 16:140

    Published on:

  42. Content type: Research article

    The link between inflammation and cancer has been confirmed by the use of anti-inflammatory therapies in cancer prevention and treatment. 5-aminosalicylic acid (5-ASA) was shown to decrease the growth and surv...

    Authors: Mona M. Saber, May A. Galal, Afaf A. Ain-Shoka and Samia A. Shouman

    Citation: BMC Cancer 2016 16:126

    Published on:

  43. Content type: Research article

    Lung cancer is the leading cause of cancer-related mortality, and new therapeutic options are urgently needed. Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancers, with the c...

    Authors: Colin Charles Tièche, Ren-Wang Peng, Patrick Dorn, Laurène Froment, Ralph Alexander Schmid and Thomas Michael Marti

    Citation: BMC Cancer 2016 16:125

    Published on:

  44. Content type: Research article

    c-Met is the receptor tyrosine kinase for hepatocyte growth factor (HGF) encoded by the MET proto-oncogene. Aberrant activation of c-Met resulting from MET amplification and c-Met overexpression is associated wit...

    Authors: Jieyi Wang, Liliane Goetsch, Lora Tucker, Qian Zhang, Alexandra Gonzalez, Kedar S. Vaidya, Anatol Oleksijew, Erwin Boghaert, Minghao Song, Irina Sokolova, Ekaterina Pestova, Mark Anderson, William N. Pappano, Peter Ansell, Anahita Bhathena, Louie Naumovski…

    Citation: BMC Cancer 2016 16:105

    Published on:

  46. Content type: Research article

    The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development and which are dys-regulated in some cancers. In this study we examined the expression...

    Authors: Richard Morgan, Guy Simpson, Sophie Gray, Cheryl Gillett, Zsuzsanna Tabi, James Spicer, Kevin J. Harrington and Hardev S. Pandha

    Citation: BMC Cancer 2016 16:85

    Published on:

  47. Content type: Research article

    Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective chemo and targeted therapies. Cell lines and animal models, even partially reflecting tumor characteristics, ...

    Authors: Giuliana Cavalloni, Caterina Peraldo-Neia, Francesco Sassi, Giovanna Chiorino, Ivana Sarotto, Massimo Aglietta and Francesco Leone

    Citation: BMC Cancer 2016 16:90

    Published on:

  48. Content type: Research article

    E.coli type II L-asparaginase is widely used for treatment of acute lymphoblastic leukemia. However, serious side effects such as allergic or hypersensitivity reactions are common for L-asparaginase treatment....

    Authors: Vadim S. Pokrovsky, Marat D. Kazanov, Ilya N. Dyakov, Marina V. Pokrovskaya and Svetlana S. Aleksandrova

    Citation: BMC Cancer 2016 16:89

    Published on:

  49. Content type: Research article

    Pseudomonas fluorescens lectin (PFL) belongs to a recently discovered anti-HIV lectin family and induces anoikis-like cell death of MKN28 gastric cancer cells by causing α2 integrin internalization through recogn...

    Authors: Yuichiro Sato, Takanori Kubo, Kinjiro Morimoto, Kazuyoshi Yanagihara and Toshio Seyama

    Citation: BMC Cancer 2016 16:63

    Published on:

  50. Content type: Research article

    Photoimmunotherapy (PIT) is a novel type of molecular optical imaging-guided cancer phototherapy based on a monoclonal antibody conjugated to a photosensitizer, IR700, in combination with near-infrared (NIR) l...

    Authors: Kimihiro Ito, Makoto Mitsunaga, Seiji Arihiro, Masayuki Saruta, Mika Matsuoka, Hisataka Kobayashi and Hisao Tajiri

    Citation: BMC Cancer 2016 16:37

    Published on:

Submit a manuscript

Follow

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us